TITLE:
Serum Calprotectin and Prealbumin Levels among Ovarian Cancer Patients Aged 30 - 45 Years
AUTHORS:
Anastasia Petsa, Vasilios Pergialiotis, Panagiotis Konstantopoulos, Athanasia Katsichti, Kyriakos Petrou, Athanasios Giannopoulos, Dimitrios Botsis, Despina Perrea
KEYWORDS:
CA-125, Calprotectin, Ovarian Cancer, Prealbumin
JOURNAL NAME:
Open Journal of Obstetrics and Gynecology,
Vol.7 No.3,
March
22,
2017
ABSTRACT: Purpose: Serum calprotectin and prealbumin have been previously linked with ovarian cancer. However, to date, their effectiveness in the diagnosis of the disease remains uncertain. The purpose of the present study is to determine whether serum prealbumin and calprotectin correlate with the stage and type of histologic diagnosis. Materials-Methods: In the present study, we included 80 women aged 30 - 45 years that had either primary ovarian cancer (Stages 1 and 2) with elevated levels of CA-125 (n = 40) or were healthy (n = 40). Serum calprotectin and prealbumin levels were assessed using ELISA kits. Statistical analysis was performed with SPSS v.20.0 statistical software. Results: Both plasma prealbumin and calprotectin levels were significantly different in patients with ovarian cancer compared to healthy controls. Specifically, serum prealbumin levels showed a level towards decreasing as the stage of the disease advanced (21.2 (15.5 - 30.6) in healthy controls, 12.8 (6.9 - 16) for patients with stage 1 disease and 9.9 (4.0 - 15.5) for patients with stage 2 disease p p Conclusions: Both prealbumin and calprotectin seem to be useful markers for the identification of patients suffering from ovarian cancer.